LONDON and PHILADELPHIA, December 17, 2025 — Avacta Therapeutics, a clinical-stage biopharmaceutical company, has reported positive Phase 1b clinical data for faridoxorubicin (AVA6000), demonstrating clinically meaningful tumor shrinkage in patients with salivary gland cancers (SGC). The interim results from the ongoing trial reinforce earlier Phase 1a findings and establish further proof-of-concept for Avacta’s proprietary pre|CISION® tumor-activated drug delivery platform, which is designed to selectively release potent chemotherapy within the tumor microenvironment.
Science Significance
The scientific importance of these findings lies in the novel peptide drug conjugate (PDC) design of faridoxorubicin, which combines the cytotoxic agent doxorubicin with Avacta’s pre|CISION® peptide. This peptide is selectively cleaved by fibroblast activation protein-alpha (FAP), an enzyme overexpressed in the tumor microenvironment of many solid tumors. By enabling tumor-specific activation of chemotherapy, AVA6000 aims to improve the therapeutic index, maximizing anti-tumor activity while minimizing systemic toxicity. In the combined Phase 1a and 1b salivary gland cancer population, the drug achieved a 90% disease control rate, with confirmed partial and minor responses measured by RECIST v1.1, highlighting durable anti-tumor activity in a cancer type historically resistant to chemotherapy.
Regulatory Significance
From a regulatory perspective, the Phase 1b data represent a critical milestone in early-stage oncology development. The study adheres to Good Clinical Practice (GCP) standards and uses regulatory-recognized efficacy endpoints, including objective response and progression-free survival. Demonstration of meaningful tumor shrinkage and a favorable safety profile supports continued cohort expansion and ongoing enrollment, while informing dose optimization strategies. These data strengthen the regulatory foundation for subsequent Phase 2 development discussions, particularly in rare cancers with high unmet medical need and no established standard of care.
Business Significance
Advertisement
For Avacta, the results significantly enhance the strategic and commercial value of its oncology pipeline. AVA6000 is the first PDC in clinical development using the pre|CISION® platform, and successful validation in Phase 1b increases confidence across the broader portfolio of pre|CISION® peptide and Affimer® drug conjugates. Positive clinical signals in salivary gland cancer, a niche but challenging indication, may open opportunities for partnerships, platform licensing, and expansion into additional solid tumors. Continued favorable data could also strengthen investor confidence by demonstrating differentiated science in a competitive oncology landscape.
Patients’ Significance
For patients with salivary gland cancers, the findings are particularly meaningful. SGC accounts for a small but devastating subset of head and neck cancers and is characterized by poor response to conventional chemotherapy, lack of approved therapies in the metastatic setting, and limited treatment options. The observed clinically meaningful tumor shrinkage and prolonged progression-free survival signals suggest that AVA6000 may represent a new therapeutic option for patients who currently face poor prognoses. Importantly, the tumor-targeted mechanism is intended to reduce off-target toxicity, potentially improving tolerability and quality of life during treatment.
Policy Significance
At a policy level, the development of AVA6000 aligns with broader healthcare priorities focused on precision oncology, rare cancer research, and innovation in drug delivery technologies. Regulators and health systems increasingly encourage therapies that improve efficacy while reducing systemic toxicity and healthcare burden. The advancement of tumor-activated therapies also supports policy goals aimed at accelerating development pathways for rare and underserved cancer populations, where traditional large trials are challenging and unmet need is substantial.
The positive Phase 1b data for faridoxorubicin (AVA6000) underscore the potential of tumor-activated peptide drug conjugates to transform the treatment of difficult-to-treat solid tumors. By demonstrating robust disease control and meaningful tumor shrinkage in salivary gland cancer, Avacta Therapeutics has strengthened the clinical and scientific rationale for its pre|CISION® platform. As enrollment continues and data mature into 2026, AVA6000 may emerge as a promising new approach in precision oncology, with implications extending well beyond this initial indication.
Source: Avacta Therapeutics press release
